Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Tectonic Therapeutic, Inc. publishes a filing, an earnings call transcript or a press release.

Get TECX alerts

About Alise Reicin

Alise Reicin is recorded as Board Member and CEO at Tectonic Therapeutic, Inc. (TECX). The newest filing on record that lists Alise Reicin as Board Member and CEO at Tectonic Therapeutic, Inc. (TECX) is dated April 24, 2026. Tectonic Therapeutic, Inc. reported in an 8-K filed June 20, 2024 that Alise Reicin was appointed Chief Executive Officer and principal executive officer, effective June 20, 2024. The proxy statement of Tectonic Therapeutic, Inc. reports total compensation of $7,351,578 for Alise Reicin in fiscal 2025, including a base salary of $640,833. Disclosed compensation is on record for 2 fiscal years. Alise Reicin has spoken on 2 investor events across 1 company, most recently for Tectonic Therapeutic, Inc. on November 11, 2026. Tectonic Therapeutic, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Tectonic Therapeutic, Inc. includes Alise Reicin, M.D. (CEO and Board Member), Erik Ostrowski (CEO), François Nader (Chairman and Board Member) and 7 others.

“On June 20, 2024, the Company's board of directors appointed Alise Reicin, M.D. as the Chief Executive Officer and principal executive officer”
Tectonic Therapeutic, Inc. Form 8-K, filed June 20, 2024 · Read the filing

Alise Reicin on recent calls

“It'll start with our... TX45, our lead program, will have Phase II data by end of January. We will not be at J.P. Morgan, and so you can expect it sometime between J.P. Morgan and hopefully end of January.”
CEO, Stifel 2026 Healthcare Conference ·
“Today, we'll be reviewing the top line results from Part B of our Phase 1B clinical trial, which evaluated the safety and hemodynamic effects associated with the single dose of TX45 in patients with pulmonary hypertension associated with reduced ejection fraction heart failure, and we'll be referring to this as PH…”
CEO, TX45 Phase 1b (Part B) PH-HFrEF Data Conference Call ·

Affiliation history

Company network

Leadership on record at Tectonic Therapeutic, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Tectonic Therapeutic, Inc. (TECX) $640,833 $7,351,578
2024 Tectonic Therapeutic, Inc. (TECX) $606,151 $5,900,979

Recent activity